Skip to main content
Erschienen in: Current Treatment Options in Cardiovascular Medicine 7/2016

01.07.2016 | Cardio-oncology (M Fradley, Section Editor)

Use of Noninvasive Imaging in Cardiac Amyloidosis

verfasst von: Raymundo Alain Quintana-Quezada, MD, Syed Wamique Yusuf, MD, Jose Banchs, MD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Opinion statement

Cardiac involvement in amyloidosis is associated with poor outcomes. The standard test for the diagnosis of cardiac amyloidosis is endomyocardial biopsy but given current advances in noninvasive imaging, the diagnosis is frequently obtained or strongly suspected without biopsy. Echocardiography is the most utilized cardiac imaging modality, particularly myocardial strain measures with this modality have been found to be a predictor of clinical outcomes, superior to traditional parameters. Other known imaging modalities with new, useful protocols for this pathology include nuclear imaging and cardiac magnetic resonance (CMR). In particular, CMR has excellent sensitivity and specificity.
Literatur
1.•
Zurück zum Zitat Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96. A review of the physiopathogenesis of amyloidosis.CrossRefPubMed Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96. A review of the physiopathogenesis of amyloidosis.CrossRefPubMed
2.
Zurück zum Zitat Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med. 2000;6(6):643–51.CrossRefPubMed Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med. 2000;6(6):643–51.CrossRefPubMed
3.
Zurück zum Zitat Sousa MM, Du YS, Fernandes R, Guimaraes A, Stern D, Saraiva MJ. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci. 2001;21:7576–86.PubMed Sousa MM, Du YS, Fernandes R, Guimaraes A, Stern D, Saraiva MJ. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci. 2001;21:7576–86.PubMed
4.
Zurück zum Zitat Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, et al. Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging. 1996;17:681–6.CrossRefPubMed Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, et al. Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging. 1996;17:681–6.CrossRefPubMed
5.
Zurück zum Zitat Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun. 2002;294:309–14.CrossRefPubMed Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun. 2002;294:309–14.CrossRefPubMed
6.
Zurück zum Zitat Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–9.CrossRefPubMed Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–9.CrossRefPubMed
7.•
Zurück zum Zitat Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21:221–4. An up-to-date description of the different amyloid proteins affecting animals and humans and their nomenclature.CrossRefPubMed Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21:221–4. An up-to-date description of the different amyloid proteins affecting animals and humans and their nomenclature.CrossRefPubMed
8.
Zurück zum Zitat Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817–22.PubMed Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817–22.PubMed
9.
Zurück zum Zitat Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525–32.CrossRefPubMedPubMedCentral Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525–32.CrossRefPubMedPubMedCentral
10.•
Zurück zum Zitat Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–57. A review of 232 patients with AL cardiac amyloidosis.CrossRefPubMed Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–57. A review of 232 patients with AL cardiac amyloidosis.CrossRefPubMed
11.
Zurück zum Zitat Cornwell 3rd GG, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75(4):618–23.CrossRefPubMed Cornwell 3rd GG, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75(4):618–23.CrossRefPubMed
12.
Zurück zum Zitat Dubrey SW, Falk RH. Amyloid heart disease. Br J Hosp Med (Lond). 2010;71(2):76–82.CrossRef Dubrey SW, Falk RH. Amyloid heart disease. Br J Hosp Med (Lond). 2010;71(2):76–82.CrossRef
13.
Zurück zum Zitat Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057–62.CrossRefPubMed Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057–62.CrossRefPubMed
14.
Zurück zum Zitat Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10(3):160–84.CrossRefPubMed Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10(3):160–84.CrossRefPubMed
15.
Zurück zum Zitat Zhang F, Hu C, Dong Y, Lin MS, Liu J, Jiang X, et al. The impact of V30A mutation on transthyretin protein structural stability and cytotoxicity against neuroblastoma cells. Arch Biochem Biophys. 2013;535(2):120–7.CrossRefPubMed Zhang F, Hu C, Dong Y, Lin MS, Liu J, Jiang X, et al. The impact of V30A mutation on transthyretin protein structural stability and cytotoxicity against neuroblastoma cells. Arch Biochem Biophys. 2013;535(2):120–7.CrossRefPubMed
16.
Zurück zum Zitat Lachman HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786–91.CrossRef Lachman HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786–91.CrossRef
17.•
Zurück zum Zitat Chew C, Ziady GM, Raphael MJ, Oakley CM. The functional defect in amyloid heart disease: the “stiff heart” syndrome. Am J Cardiol. 1975;36:438–44. First description of the echocardiographic features of cardiac amyloidosis.CrossRefPubMed Chew C, Ziady GM, Raphael MJ, Oakley CM. The functional defect in amyloid heart disease: the “stiff heart” syndrome. Am J Cardiol. 1975;36:438–44. First description of the echocardiographic features of cardiac amyloidosis.CrossRefPubMed
18.
Zurück zum Zitat Cueto-Garcia L, Tajik AJ, Kyle RA, Edwards WD, Greipp PR, Callahan JA, et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc. 1984;59(9):589–97.CrossRefPubMed Cueto-Garcia L, Tajik AJ, Kyle RA, Edwards WD, Greipp PR, Callahan JA, et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc. 1984;59(9):589–97.CrossRefPubMed
19.
Zurück zum Zitat Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004;43(3):410–5.CrossRefPubMed Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004;43(3):410–5.CrossRefPubMed
20.
Zurück zum Zitat Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101–10.CrossRefPubMed Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101–10.CrossRefPubMed
21.
Zurück zum Zitat Simons M, Isner JM. Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. Am J Cardiol. 1992;69:425–7.CrossRefPubMed Simons M, Isner JM. Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. Am J Cardiol. 1992;69:425–7.CrossRefPubMed
22.
Zurück zum Zitat Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990;16:1135–41.CrossRefPubMed Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990;16:1135–41.CrossRefPubMed
23.
Zurück zum Zitat Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.CrossRefPubMed Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.CrossRefPubMed
24.
Zurück zum Zitat Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–60.CrossRefPubMed Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–60.CrossRefPubMed
25.
Zurück zum Zitat Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165(12):1425–9.CrossRefPubMed Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165(12):1425–9.CrossRefPubMed
26.
Zurück zum Zitat Klein AL, Hatle LK, Burstow DJ, Seward JB, Kyle RA, Bailey KR, et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1989;13(5):1017–26.CrossRefPubMed Klein AL, Hatle LK, Burstow DJ, Seward JB, Kyle RA, Bailey KR, et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1989;13(5):1017–26.CrossRefPubMed
27.
Zurück zum Zitat Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991;83(3):808–16.CrossRefPubMed Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991;83(3):808–16.CrossRefPubMed
28.
Zurück zum Zitat Porciani MC, Cappelli F, Perfetto F, Ciaccheri M, Castelli G, Ricceri I, et al. Rotational mechanics of the left ventricle in AL amyloidosis. Echocardiography. 2010;27(9):1061–8.CrossRefPubMed Porciani MC, Cappelli F, Perfetto F, Ciaccheri M, Castelli G, Ricceri I, et al. Rotational mechanics of the left ventricle in AL amyloidosis. Echocardiography. 2010;27(9):1061–8.CrossRefPubMed
29.
Zurück zum Zitat Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107(19):2446–52.CrossRefPubMed Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107(19):2446–52.CrossRefPubMed
30.
Zurück zum Zitat Ogiwara F, Koyama J, Ikeda S, Kinoshita O, Falk RH. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol. 2005;95(4):538–40.CrossRefPubMed Ogiwara F, Koyama J, Ikeda S, Kinoshita O, Falk RH. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol. 2005;95(4):538–40.CrossRefPubMed
31.
Zurück zum Zitat Bellavia D, Pellikka PA, Abraham TP, Al-Zahrani GB, Dispenzieri A, Oh JK, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol. 2008;101(7):1039–45.CrossRefPubMed Bellavia D, Pellikka PA, Abraham TP, Al-Zahrani GB, Dispenzieri A, Oh JK, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol. 2008;101(7):1039–45.CrossRefPubMed
32.
Zurück zum Zitat Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3(4):333–42.CrossRefPubMed Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3(4):333–42.CrossRefPubMed
33.
Zurück zum Zitat Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009;103(3):411–5.CrossRefPubMed Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009;103(3):411–5.CrossRefPubMed
34.•
Zurück zum Zitat Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442–8. A study comparing patients with CA versus LV hypertrophy of multiple etiologies showed regional variations in longitudinal strain from base to apex can help recognizing CA.CrossRefPubMed Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442–8. A study comparing patients with CA versus LV hypertrophy of multiple etiologies showed regional variations in longitudinal strain from base to apex can help recognizing CA.CrossRefPubMed
35.
Zurück zum Zitat Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840–9.CrossRefPubMed Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840–9.CrossRefPubMed
36.
Zurück zum Zitat Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging. 2002;29(3):376–9.CrossRefPubMed Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging. 2002;29(3):376–9.CrossRefPubMed
37.•
Zurück zum Zitat Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–84. This study shows the utility of Tc-99m-DPD scintigraphy in the workup to differentiate TTR versus AL etiology.CrossRefPubMed Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–84. This study shows the utility of Tc-99m-DPD scintigraphy in the workup to differentiate TTR versus AL etiology.CrossRefPubMed
38.
Zurück zum Zitat Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2 propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470–8.CrossRefPubMed Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2 propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470–8.CrossRefPubMed
39.
Zurück zum Zitat Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7(5):531–2.CrossRefPubMed Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7(5):531–2.CrossRefPubMed
40.
Zurück zum Zitat González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94.CrossRefPubMed González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94.CrossRefPubMed
41.
Zurück zum Zitat Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659–70.CrossRefPubMed Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659–70.CrossRefPubMed
42.
Zurück zum Zitat Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22(1):22–31.PubMed Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22(1):22–31.PubMed
43.
Zurück zum Zitat Nakata T, Shimamoto K, Yonekura S, Kobayashi N, Sugiyama T, Imai K, et al. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-12-MIBG. J Nucl Med. 1995;36:1040–2.PubMed Nakata T, Shimamoto K, Yonekura S, Kobayashi N, Sugiyama T, Imai K, et al. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-12-MIBG. J Nucl Med. 1995;36:1040–2.PubMed
44.
Zurück zum Zitat Tanaka M, Hongo M, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol. 1997;29(1):168–74.CrossRefPubMed Tanaka M, Hongo M, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol. 1997;29(1):168–74.CrossRefPubMed
45.
Zurück zum Zitat Noordzij W, Glaudemans AW, van Rheenen RW, Hazenberg BP, Tio RA, Dierckx RA, et al. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging. 2012;39(10):1609–17.CrossRefPubMedPubMedCentral Noordzij W, Glaudemans AW, van Rheenen RW, Hazenberg BP, Tio RA, Dierckx RA, et al. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging. 2012;39(10):1609–17.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213–20.CrossRefPubMed Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213–20.CrossRefPubMed
47.
Zurück zum Zitat Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015;8(1):50–9.CrossRefPubMed Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015;8(1):50–9.CrossRefPubMed
48.
Zurück zum Zitat Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26(15):1461–74.CrossRefPubMed Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26(15):1461–74.CrossRefPubMed
49.
Zurück zum Zitat Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51(10):1022–30.CrossRefPubMed Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51(10):1022–30.CrossRefPubMed
50.
Zurück zum Zitat Saeed M, Wagner S, Wendland MF, Derugin N, Finkbeiner WE, Higgins CB. Occlusive and reperfused myocardial infarcts: differentiation with Mn-DPDP—enhanced MR imaging. Radiology. 1989;172:59–64.CrossRefPubMed Saeed M, Wagner S, Wendland MF, Derugin N, Finkbeiner WE, Higgins CB. Occlusive and reperfused myocardial infarcts: differentiation with Mn-DPDP—enhanced MR imaging. Radiology. 1989;172:59–64.CrossRefPubMed
51.
Zurück zum Zitat Wesbey GE, Higgins CB, McNamara MT, Engelstad BL, Lipton MJ, Sievers R, et al. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology. 1984;153:165–9.CrossRefPubMed Wesbey GE, Higgins CB, McNamara MT, Engelstad BL, Lipton MJ, Sievers R, et al. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology. 1984;153:165–9.CrossRefPubMed
52.
Zurück zum Zitat Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial gadolinium-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–26.CrossRefPubMed Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial gadolinium-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–26.CrossRefPubMed
53.
Zurück zum Zitat Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology. 2001;218:703–10.CrossRefPubMed Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology. 2001;218:703–10.CrossRefPubMed
54.
Zurück zum Zitat Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–26.CrossRefPubMed Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318–26.CrossRefPubMed
55.
Zurück zum Zitat Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.CrossRefPubMed Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.CrossRefPubMed
56.•
Zurück zum Zitat Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10:54. A study showing gadolinium kinetics can predict survival in patients with CA.CrossRefPubMedPubMedCentral Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10:54. A study showing gadolinium kinetics can predict survival in patients with CA.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138–44.CrossRefPubMed Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138–44.CrossRefPubMed
58.
Zurück zum Zitat Brooks J, Kramer CM, Salerno M. Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T mapping. J Magn Reson Imaging. 2013;38:1591–5.CrossRefPubMed Brooks J, Kramer CM, Salerno M. Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T mapping. J Magn Reson Imaging. 2013;38:1591–5.CrossRefPubMed
59.
Zurück zum Zitat Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012;5:897–907.CrossRefPubMedPubMedCentral Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012;5:897–907.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–51.CrossRefPubMed Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–51.CrossRefPubMed
61.•
Zurück zum Zitat Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–9. Largest CMR study in AL and ATTR patients showing PSIR technique is more accurate than standard techniques and amyloid deposition in the heart is a continuum.CrossRefPubMedPubMedCentral Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–9. Largest CMR study in AL and ATTR patients showing PSIR technique is more accurate than standard techniques and amyloid deposition in the heart is a continuum.CrossRefPubMedPubMedCentral
Metadaten
Titel
Use of Noninvasive Imaging in Cardiac Amyloidosis
verfasst von
Raymundo Alain Quintana-Quezada, MD
Syed Wamique Yusuf, MD
Jose Banchs, MD
Publikationsdatum
01.07.2016
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 7/2016
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-016-0469-3

Weitere Artikel der Ausgabe 7/2016

Current Treatment Options in Cardiovascular Medicine 7/2016 Zur Ausgabe

Vascular Disease (I Weinberg, Section Editor)

Interventions for Varicose Veins: Beyond Ablation

Cardio-oncology (M Fradley, Section Editor)

Late Cardiotoxicity: Issues for Childhood Cancer Survivors

Cardio-oncology (M Fradley, Section Editor)

Cardiovascular Complications of Cranial and Neck Radiation

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.